Aceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing
30 Maio 2023 - 5:25PM
Aceragen, Inc. (the “Company”) (Nasdaq: ACGN), announced today that
on May 24, 2023, the Company received a notice from The Nasdaq
Stock Market LLC (“Nasdaq”) stating that because the Company had
not yet filed its Quarterly Report on Form 10-Q for the quarterly
period ended March 31, 2023 (the “Form 10-Q”), the Company is not
in compliance with Nasdaq Listing Rule 5250(c)(1), which requires
timely filing of periodic financial reports with the Securities and
Exchange Commission. The Nasdaq notice has no immediate effect on
the listing or trading of the Company’s common stock on The Nasdaq
Global Market. The Company has until July 24, 2023 to submit to
Nasdaq a plan to regain compliance. If Nasdaq accepts the Company’s
plan, then Nasdaq may grant the Company up to 180 calendar days
from the Form 10-Q’s original due date, or November 20, 2023, to
regain compliance. If the Company is unable to make such filings by
July 24, 2023, the Company intends to submit to Nasdaq a plan to
regain compliance.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements, other than statements of historical fact, included
or incorporated in this press release, including, without
limitation, statements regarding the Company's ability to regain
compliance with Nasdaq listing standards, are forward-looking
statements. The words "believes," "anticipates," "estimates,"
"plans," "expects," "intends," "may," "could," "should,"
"potential," "likely," "projects," "continue," "will," "schedule,"
and "would" and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. These forward-looking
statements are predictions based on our current expectations and
projections about future events and various assumptions. We cannot
guarantee that we will achieve the plans, intentions, or
expectations disclosed in our forward-looking statements and you
should not place undue reliance on our forward-looking statements.
These forward-looking statements involve known and unknown risks,
uncertainties, and other factors, which may be beyond our control,
and which may cause our actual results, performance, or
achievements to differ materially from future results, performance,
or achievements expressed or implied by such forward-looking
statements. There are a number of important factors that could
cause our actual results to differ materially from those indicated
or implied by its forward-looking statements including, without
limitation, whether our cash resources will be sufficient to fund
continuing operations and allow us to comply with regulatory and
stock exchange listing requirements. All forward-looking statements
included in this press release are made as of the date hereof and
are expressly qualified in their entirety by this cautionary
notice, including, without limitation, those risks and
uncertainties described in the Company’s Annual Report on Form 10-K
for the year ended December 31, 2022, and otherwise in the
Company’s subsequent filings and reports filed with Securities and
Exchange Commission. The Company does not assume any obligation to
update any forward-looking statements and it disclaims any
intention or obligation to update or revise any forward-looking
statement, whether as a result of new information, future events,
or otherwise, except as may be required by law.
Contact: |
Aceragen, Inc.John Taylor |
Jtaylor@aceragen.com |
Aceragen (NASDAQ:ACGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Aceragen (NASDAQ:ACGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024